This month’s investment candidate is Resverlogix (RVXCF). Using a revolutionary new science called epigenetics, which changes a person’s genetic function without actually altering their DNA, the Canadian biotech is set to introduce a first-in-class drug for treating cardiovascular disease—the leading cause of death around the world.
